Critics of health-care consolidation have cited higher costs of chemotherapy administration as an example of how mergers drive up costs. A new study by Kalidindi et al in The American Journal of Managed Care found that although drug administration costs in hospitals are higher, chemotherapy drug spending among Medicare patients is lower, driven by less frequent use of therapy.
The findings conflict with analyses cited by community oncology advocates, who have argued that health-care consolidation, driven in part by the 340B discount drug program, has pushed more patients with cancer into hospital outpatient clinics for care—and higher chemotherapy costs are the result. In this new study, funded by the National Institutes of Health, researchers led by Yamini Kalidindi, MHA, of Penn State University, compared raw Medicare per capita chemotherapy costs between hospitals and physicians’ offices, as well as per capita costs controlling for cancer type.
“Spending differences in commercial settings are driven by price differences between [hospital outpatient departments] and physician offices rather than differences in quantities of services,” the authors write. “Medicare uses the same reimbursement rates for chemotherapy drugs in both settings.”
Analyzing costs by cancer type showed that once one controls for the different types of cancers seen in the two settings, Medicare per capita drug costs are lower in the hospital. However, chemotherapy administration costs are higher in hospitals, as community oncology advocates claim. The researchers do note that the chemotherapy spending per claim is higher in the hospital compared with physician offices—most likely driven by differences in treatment mix between the settings.
An accompanying editorial by Kavita Patel, MD, MPH, of the Brookings Institution, and A. Mark Fendrick, MD, of the University of Michigan, noted that the analysis covers years before Medicare launched the value-based Oncology Care Model (OCM) and that “early findings from the OCM have demonstrated signs of progress.”
Using claims data from 2010 to 2013 for a random sample of Medicare fee-for-service members with cancer, the researchers found:
Drs. Patel and Fendrick said the findings have important implications as the Trump Administration weighs whether to consolidate Medicare Part D with Medicare Part B, as the latter program pays for physician-administered chemotherapy drugs. The Trump Administration’s proposal is part of a broader effort to rein in drug costs. At the same time, hospitals are resisting changes to the 340B program that community practices say would even the playing field and halt the wave of consolidation.
The editorial also notes that the results come as the 21st Century Cures Act calls for site-neutral reimbursement to new Medicare facilities. “The interpretation of the results of site-of-care research may have even more far-reaching consequences as pressure grows to extend site-neutral payment policies from new to existing facilities,” Drs. Patel and Fendrick wrote.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.